Simply put:
https://www.tipranks.com/news/company-announcements/telix-reports-promising-prostate-cancer-trial-results
Telix Pharmaceuticals Ltd. has shared promising results from their ProstACT SELECT trial, showing a median radiographic progression-free survival of 8.8 months for their TLX591 therapy in treating metastatic castrate-resistant prostate cancer. TLX591, a lutetium-labelled radio-antibody drug conjugate, also demonstrated a favorable safety profile and is now advancing to a Phase III trial. The company emphasizes TLX591’s potential benefits, including a patient-friendly dosing regimen and lower radiation exposure compared to existing treatments.
Simply...
-
- There are more pages in this discussion • 179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.22 |
Change
0.060(0.28%) |
Mkt cap ! $7.101B | |||
| Open | High | Low | Value | Volume |
| $21.14 | $21.40 | $20.75 | $16.20M | 767.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 120 | $21.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.25 | 457 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |